Crinetics announces early release of ENDO 2024 late-breaking abstracts for atumelnant Phase 2 CAH study

Crinetics Pharmaceuticals, Inc.

Late-breaking abstracts for atumelnant (CRN04894) Phase 2 CAH study released before embargo.
Abstract contained summary data on 4 subjects; data from 6 subjects in cohort 1 and cohort 2 to be presented June 3, 2024.
Full data set will be presented at ENDO 2024 poster session on June 1-2 pm ET.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.